Endothelin receptor antagonism in patients with chronic heart failure.
暂无分享,去创建一个
D. Webb | J. McMurray | A. Davenport | M. Love | C. Plumpton | C. Ferro | W. Haynes
[1] D. Webb,et al. Venous endothelin receptor function in patients with chronic heart failure. , 2000, Clinical science.
[2] M. Böhm,et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. , 1999, Circulation.
[3] D. Webb,et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. , 1999, Hypertension.
[4] A. Davenport,et al. Increased response to big endothelin‐1 in atherosclerotic human coronary artery: functional evidence for up‐regulation of endothelin‐converting enzyme activity in disease , 1998, British journal of pharmacology.
[5] D. Webb,et al. Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade Mediated Vasodilatation Is Attenuated by Inhibition of − Endothelin-A Receptor Antagonist , 1998 .
[6] J. McMurray,et al. EndothelinBreceptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction , 1998 .
[7] P. Vallance,et al. Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. , 2003, British journal of clinical pharmacology.
[8] D. Fukai,et al. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. , 1997, Journal of the American College of Cardiology.
[9] F. Lallemand,et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.
[10] J. Kastrup,et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. , 1996, Cardiovascular research.
[11] Y. Sugishita,et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.
[12] D. Webb,et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. , 1996, Circulation.
[13] J. McMurray,et al. Endothelin in chronic heart failure: current position and future prospects. , 1996, Cardiovascular research.
[14] Y. Sugishita,et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. , 1996, Circulation.
[15] G. Maurer,et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.
[16] A. Lerman,et al. Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure , 1996 .
[17] P. Hunziker,et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.
[18] D. Webb,et al. Phosphoramidon inhibition of the in vivo conversion of big endothelin‐1 to endothelin‐1 in the human forearm , 1995, British journal of pharmacology.
[19] D. Webb,et al. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. , 1995, Circulation.
[20] P Vallance,et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. , 1995, Hypertension.
[21] G. Ahlborg,et al. Metabolism of Big endothelin-1 (1–38) and (22–38) in the human circulation in relation to production of endothelin-1 (1–21) , 1995, Regulatory Peptides.
[22] D. Webb,et al. Measurement of C‐Terminal Fragment of Big Endothelin‐1: A Novel Method for Assessing the Generation of Endothelin‐1 in Humans , 1995, Journal of cardiovascular pharmacology.
[23] D. Guédin,et al. Why are circulating concentrations of endothelin-1 so low? , 1994, Cardiovascular research.
[24] D. Webb,et al. Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.
[25] M. Yanagisawa,et al. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 , 1994, Cell.
[26] T. Nagase,et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] W. Edwards,et al. Endothelin in human congestive heart failure. , 1994, Circulation.
[28] L. V. von Segesser,et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. , 1994, Circulation.
[29] T. Fukami,et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. , 1992, Life sciences.
[30] S. Nakanishi,et al. Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.
[31] T. Sakurai,et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor , 1990, Nature.
[32] J. Vane,et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[33] B. Robinson,et al. Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. , 1978, British journal of clinical pharmacology.